Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prime Medicine, Inc.

1.69
+0.330024.26%
Post-market: 1.68-0.0100-0.59%19:55 EDT
Volume:4.96M
Turnover:8.02M
Market Cap:216.02M
PE:-1.05
High:1.71
Open:1.42
Low:1.40
Close:1.36
Loading ...

Prime Medicine Announces Leadership Transition: Dr. Allan Reine Appointed CEO as Keith Gottesdiener Steps Down

Reuters
·
19 May

Prime Medicine Inc - Allan Reine Appointed CEO of Prime Medicine

THOMSON REUTERS
·
19 May

Prime Medicine Inc - in Arbitration With Beam Therapeutics Over Aatd Program

THOMSON REUTERS
·
19 May

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

THOMSON REUTERS
·
19 May

Press Release: Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

Dow Jones
·
19 May

Prime Medicine Announces Promising Initial Clinical Data for PM359 in Chronic Granulomatous Disease Trial

Reuters
·
19 May

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of Dhr Positivity After Single Infusion of Pm359, an Investigational Prime Editor for Chronic Granulomatous Disease

THOMSON REUTERS
·
19 May

Prime Medicine sees cash runway into 1H26

TIPRANKS
·
08 May

Prime Medicine Q1 EPS $(0.40) Misses $(0.36) Estimate, Sales $1.45M Beat $1.05M Estimate

Benzinga
·
08 May

Prime Medicine - Initial Data From Phase 1/2 Trial of Pm359 for P47(Phox) Cgd Expected in 2025

THOMSON REUTERS
·
08 May

Prime Medicine, Inc. Q1 EPS USD -0.4

THOMSON REUTERS
·
08 May

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Why Prime Medicine Stock Was Climbing Higher This Week

Motley Fool
·
21 Mar

Prime Medicine Is Maintained at Buy by Chardan Capital

Dow Jones
·
20 Mar

Prime Medicine price target raised to $16 from $15 at Chardan

TIPRANKS
·
20 Mar

Chardan Raises Price Target on Prime Medicine to $16 From $15, Keeps Buy Rating

MT Newswires Live
·
20 Mar

Prime Medicine, Inc.: Promising Future in Gene Editing with Innovative AATD Program and Strategic Growth Potential

TIPRANKS
·
19 Mar

Prime Medicine Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Mar

Prime Medicine, Inc.: Innovative Prime Editing Technology and Promising Preclinical Results Drive Buy Rating

TIPRANKS
·
19 Mar

Wedbush Adjusts Prime Medicine Price Target to $13 From $12, Maintains Outperform Rating

MT Newswires Live
·
19 Mar